RESEARCH Open Access

A

Daisy Higginson[1†]

Background

D [illegible] I [illegible] I [illegible] D [illegible] J [illegible] “ [illegible] ... [illegible] ” [illegible] I [illegible] I [illegible]

CHNRI exercise – stage I: Identification and selection of studies

CHNRI exercise – stage II



Table 1 Summary of major clinical trials on aerosol measles vaccines presented to the expert group for stage II of the CHNRI process

Reference	MV Strain	Age group	Seroconversion as defined by authors
A.Dilraj et al [46]	MV-Schwarz (s/c, aerosol), MV- Edmonston-Zagreb (s/c, aerosol)	992 participants 5-14 years	Seroconversion rates (defined as four fold increase in antibody level): EZ Aerosol – 84.7% EZ sc – 78.8% SW Aerosol – 22.7% SW sc – 62.6%
A.Dilraj et al [47]	MV-Schwarz (s/c), MV- Edmonston-Zagreb (s/c, aerosol)	337 participants	

Intervention



$

I

I

Cost



Local and context-specific factors

[illegible]

Conclusions

[illegible]

Additional material

Additional file 1: Supplementary tables: Supplementary Table 1: Details of search strategy for identifying studies reporting aerosolised measles vaccine Supplementary Table 2: Questions used in the Phase II CHNRI process.

Acknowledgements
This work was supported by the grant from the Bill and Melinda Gates Foundation No. 51285 ("Modelling the impact of emerging interventions against pneumonia").